Full-Time

Technical Associate 2

Posted on 6/6/2026

Deadline 6/11/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$20.07 - $33.45/hr

+ Overtime pay premiums

No H1B Sponsorship

Kalamazoo, MI, USA

In Person

Third shift (10:00 PM–6:30 AM); weekend/holiday/overtime required; relocation assistance may be available.

Category
Biology & Biotech (1)
Required Skills
Microbiology
Requirements
  • High School Diploma or GED with 2+ years of relevant experience
  • Basic math and computer skills such as data entry
  • Understanding of equipment, instrumentation, and computer applications
  • High productivity and the ability to multi-task
  • Ability to read, comprehend, and follow procedures
  • Good oral, written, and interpersonal communication skills within a diverse team setting
  • Experience in a GMP environment
  • Quality Control experience
  • Strong problem-solving and analytical skills
  • Ability to work independently with moderate supervision
  • Familiarity and basic understanding of common AI tools and a curiosity for learning how they can be used to enhance productivity
Responsibilities
  • Take responsibility for individual contributions to achieve team deliverables, working effectively as a team member and coordinating with others.
  • Manage personal time and professional development, being accountable for results.
  • Follow standard procedures to complete tasks of varying scope, sequence, and complexity within the agreed timeframe.
  • Identify and solve moderately routine problems.
  • Complete assignments with moderate supervision using established procedures, referring deviations from standard procedures to the supervisor.
  • Operate efficiently in a fast-paced, customer-oriented team environment, providing support to our Operations partners.
  • Complete training activities, maintain records, equipment, basic lab supplies in compliance with Current Good Manufacturing Practices (part of GxP) requirements.
  • Participate in laboratory investigations.
  • Using standardized procedures, the candidate will conduct a variety of microbiological environmental sampling in aseptic /classified processing areas. The sampling performed supports high through-put pharmaceutical manufacturing.
  • Within our Manufacturing facilities, provide real-time feedback/guidance within the scope of Aseptic Observations program. This includes good documentation practices, ability to manage time independently and collaborate with others within the facility to ensure compliance.
  • In addition to performance of routine environmental sampling, the candidate will assist in the overall operation of the microbiology laboratory including incubation of samples, read out of sample results and entry of results into an electronic database. Could second check records and assist in training others.
  • Interpret and evaluate data in terms of accuracy, precision, trends, and potential Good Manufacturing Practices (cGMP) impact and recommend appropriate corrective action where necessary.
  • Adhere to safe work practices, such as wearing appropriate personal protective equipment including lab coat, safety glasses, and gloves.
  • In production areas, adhere to gowning procedures and practices (i.e. aseptic gowning).
  • Perform equipment verification and calibration in accordance with procedures.
  • Maintain area and equipment in clean, safe, functional order.
  • Primary responsibilities are to perform environmental sampling and Aseptic Observation (real-time, direct feedback in production settings) in aseptic/classified processing areas.
  • This includes setting up sampling materials and data summaries in a computerized database, incubating samples, interpreting, and documenting results.
  • Recognize atypical data and inform supervision of relevant problems.
  • Enter, review, and approve data in a computerized database.
  • Transport samples and supplies between the laboratory and production environments.
  • Apply technical knowledge of microbiological principles, theories, concepts, and Pfizer processes and industry practices/standards to daily work.
  • Be able to work both independently and as part of a team.
  • Operate within established Px policies and basic colleague relations guidelines.
  • Contribute to the completion of specific team objectives and assigned project milestones.
Desired Qualifications
  • Quality Control experience
  • Strong problem-solving and analytical skills
  • Ability to work independently with moderate supervision
  • Familiarity and basic understanding of common AI tools and a curiosity for learning how they can be used to enhance productivity

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Your Connections

People at Pfizer who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • HYMPAVZI’s pediatric expansion broadens Pfizer’s hemophilia reach in an underserved segment.
  • The Innovent deal adds twelve oncology programs and diversifies growth beyond patent-cliff products.
  • A 6.6% dividend yield and cost-savings targets support investor appeal and margin resilience.

What critics are saying

  • Eliquis exclusivity loss in 2027-2028 threatens one of Pfizer’s largest cash generators.
  • Ibrance patent expiry in 2027 will compress oncology revenue as generics enter.
  • Declining COVID product sales and upcoming Prevnar erosion keep overall revenue under pressure.

What makes Pfizer unique

  • Pfizer combines global scale, vaccines, oncology, and specialty medicines across multiple therapeutic areas.
  • Its Seagen acquisition strengthened oncology with assets like Padcev and broader cancer capabilities.
  • Pfizer also uses AI licensing, including Chai Discovery, to accelerate drug discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

2%
Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE